Olemedia
Greenwich LifeSciences (NASDAQ:GLSI) traded higher on Wednesday after the immunotherapy developer updated on the commercial manufacturing of its lead candidate GP2, which is currently undergoing a late-stage trial called FLAMINGO-01 for breast cancer.
Noting that commercial manufacturing data as well